09:15 AM EST, 01/10/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) and Samsung Bioepis said Friday that they have signed an agreement to develop and commercialize Epysqli, Samsung Bioepis' biosimilar to Alexion Pharmaceuticals' Soliris, in the US.

Under the terms of the deal, Samsung Bioepis will oversee the development, regulatory registration, manufacture, and supply of Epysqli, while Teva will be responsible for its commercialization in the US.

Financial terms were not disclosed.